Quinvaxem injection is a ready-to-use, fully liquid combined vaccine containing diphtheria and tetanus toxoids, inactivated whole cell pertussis component, hepatitis B surface antigen (HBsAg) and H. influenzae type b component. Qunivaxem is indicated for active immunisation of infants and toddlers for protection against diphtheria, tetanus, pertussis, hepatitis B, and invasive illness caused by H. influenzae type b. Can be used interchangeably with other DTP-HepB-Hib vaccines.
Primary vaccination of infants (first year of life) with 3 doses of 0.5 ml each, at least one month apart, starting as early as 6 weeks of age. Can be given to children who have received hepatitis B vaccine at birth. Should not be used for hepatitis B vaccination at birth. Reinforcing vaccination of toddlers (13–24 months after birth): one booster dose of 0.5 ml.
Intramuscular injection in the anterolateral thigh or alternatively in the deltoid region in children 13–24 months after birth. Simultaneous administration as a separate injection with other common childhood vaccines, according to locally recommended immunisation schedules is possible.
Should not be given to children: with known hypersensitivity to any vaccine component; having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines; who have experienced an encephalopathy of unknown aetiology after a previous vaccination with vaccine containing pertussis (in these cases vaccination should be continued with diphtheria, tetanus, hepatitis B and Hib vaccines). As with other vaccines, vaccination should be postponed in children suffering from acute febrile illness.